Abemaciclib Shows Promise in Aggressive Meningiomas with Specific Genetic Mutations
核心洞察
A national clinical trial led by Mass General Brigham found that abemaciclib, an oral CDK inhibitor, may slow tumor growth in patients with aggressive meningiomas carrying NF2 (搜索) mutations or CDK pathway (搜索) alterations.
Among the first 24 patients treated, 58% had high-grade tumors that didn't progress within six months, comparing favorably to historical controls of 0-29% progression-free survival at six months.
The study achieved a median progression-free survival of 10 months and median overall survival of 29 months, with manageable side effects similar to those seen in breast cancer (搜索) patients.
A national clinical trial has demonstrated that abemaciclib, an oral CDK 4/6 (搜索) inhibitor currently approved for breast cancer (搜索), shows promising activity in patients with aggressive meningiomas harboring specific genetic mutations. The Alliance A071401 trial, led by investigators at Mass General Brigham Cancer Institute (搜索) through the Alliance for Clinical Trials in Oncology, represents the first genomically-driven national study for this patient population.
Trial Design and Patient Population
The phase 2 study enrolled patients with grade 2 or 3 meningiomas whose tumors carried NF2 (搜索) mutations or CDK pathway (搜索) alterations. All 36 patients who started treatment had previously undergone surgery, and most had received radiation therapy and other medical interventions. Patients received abemaciclib at 200 mg twice daily in 28-day cycles until disease progression, unacceptable toxicity, neurological deterioration, or study withdrawal.
"Patients with recurrent or progressive high-grade meningiomas have historically had very few treatment options, and most prior trials of medical therapy have been disappointing," said senior author Priscilla Brastianos, MD, a neuro-oncologist with Mass General Brigham Cancer Institute (搜索).
Primary Efficacy Results
Among the first 24 patients evaluated, 58% achieved the primary endpoint of progression-free survival at six months (PFS6). This outcome significantly exceeded the trial's prespecified criteria, which required at least eight patients to be progression-free at that time point. The results compare favorably to historical controls, where previous studies found that only 0-29% of patients with grade 2 or 3 meningiomas remained progression-free within six months of starting experimental treatment.
Central radiology review of 21 patients confirmed that 12 patients were progression-free at six months based on Macdonald criteria and volumetric measurements. Stable disease was the best response observed in 16 of 24 patients, while no complete or partial responses were recorded.
Survival Outcomes
The median progression-free survival reached 10.1 months for the first 24 evaluable patients and 7.6 months when all 35 evaluable patients were included. Among patients whose best response was stable disease, median progression-free survival extended to 11.1 months. The median overall survival was 29.1 months for both the initial 24 patients and the full cohort of 35 evaluable patients.
Genetic Subgroup Analysis
Exploratory analyses revealed differential responses based on genetic alterations. Patients with NF2 (搜索) alterations demonstrated higher PFS6 outcomes (15 of 24 patients) compared to those with CDK pathway (搜索) alterations alone (one of four patients) or combined NF2 and CDK pathway alterations (two of seven patients).
Patients with NF2 (搜索) alterations also achieved longer median progression-free survival of 12.1 months, compared with 2.4 months for CDK pathway (搜索) patients and two months for those with both alterations. Immunohistochemistry and genetic analyses suggested higher mean p16 levels in patients who clinically benefited from abemaciclib.
Safety Profile
All 36 patients who initiated treatment were evaluable for safety, receiving an average of nine treatment cycles. The safety profile was consistent with abemaciclib's known effects in other cancer types. Common side effects included diarrhea, fatigue, headache, and nausea/vomiting.
Twelve patients experienced at least one treatment delay, and seven patients discontinued abemaciclib due to side effects. Nine patients experienced grade 3 severe side effects, while two patients had grade 4 life-threatening events, including elevated liver enzymes and vomiting, which were at least possibly related to treatment. About a quarter of patients experienced grade 3 or grade 4 adverse events deemed possibly or likely treatment-related.
Clinical Significance
Meningiomas represent the most common primary brain tumors, growing in the membranes surrounding the brain and spinal cord. While most are benign or treatable, aggressive meningiomas with mutations in genes like NF2 (搜索) and alterations in the CDK pathway (搜索) can be fatal, with extremely limited treatment options for patients whose tumors return or continue growing after surgery and radiation therapy.
"This research shows that genomically driven trials for patients with meningioma (搜索) are feasible and that targeted therapy may improve outcomes for patients with specific genetic mutations," noted Brastianos, emphasizing that this was the first national study to enroll patients based on mutational testing.
The study's results support further investigation of abemaciclib in this understudied patient population, with the treatment demonstrating manageable toxicity through dose adjustments and treatment breaks. "We are encouraged by these exciting results, but we still have more work ahead of us to improve treatments for this understudied patient population," Brastianos concluded.